A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
== Others == Endogenous Adrenomedullin Apelin Asprosin Bombesin Calcitonin Carnosine CART CLIP DSIP Enteroglucagon Formyl peptide GALP GIP GRP Integrin ligands collagens fibrinogen fibronectin laminins ICAM-1 ICAM-2 osteopontin VCAM-1 vitronectin Kininogens Motilin Natriuretic peptides ANP BNP CNP urodilatin Nesfatin-1 Neuromedin B Neuromedin N Neuromedin S Neuromedin U Obestatin Osteocalcin Resistin Secretin Thymopoietin Thymosins Thymulin Urotensin-II VGF Exogenous Lifitegrast (LFA-1 antagonist)
Then, the metabolites undergo N-methylation by non-specific N-methyltransferase(NMT) or by phenylethanolamine-N-methyltransferase (PNMT) (found in the adrenal medulla) to form secondary amines and sympathetic neurotransmitter noradrenaline. The second possible pathway is deamination of the drug by the semi-carbazide-sensitive amine oxidases (SSAO) (found in the vascular tissue and have similar metabolism to MAO). An alpha-methyl side chain renders the drug immune to deamination in the gut. The drugs are mainly excreted in feces and urine. Alprazolam has high oral bioavailability (84-91%) in which its maximum plasma concentration (Cmax) is reached after 1 to 2 hours. When taken with food, Cmax is increased by 25%. The half-life profile of this drug for different populations is illustrated in the following table:
Intensity-fading MALDI is a term coined to rename an existing method originally reported in 1999 to indirectly study a Protein–protein interaction or other protein complex and was the same year applied to a biological mixture to study the antigenicity of the influenza virus. It involves treating a protein and a potential binding partner with a site-specific endoproteinase with the binding sites identified by their reduced area (or intensity) in a MALDI mass spectrum compared to that of non-bound protein control. It was falsely reported as new and novel in a later application by a Spanish group. The true origins of the approach and a range of applications including those employing gel based separations, drug-protein interactions and the relative affinity of such interactions, are described in a review article.
Bromelain, a concentrate of proteolytic enzymes from the pineapple plant, is used in medicine. It is approved in the European Union for the debridement (removal of eschar, that is dead and damaged tissue) of severe burn wounds under the brand name Nexobrid. It was developed by MediWound. The medicine has been granted orphan drug status by the European Medicines Agency (EMA). In other contexts, bromelain has been researched for possible anti-inflammatory effects in treating a range of conditions or diseases, but results of these studies are mixed and regarded as preliminary. In December 2022, anacaulase-bcdb (Nexobrid) was approved for medical use in the United States.
Sources: en.wikipedia.org
==== Mexico ==== Taco Bell has attempted to enter the Mexican market twice. After a highly publicised launch in Mexico City in 1992, all the restaurants were closed two years later. In September 2007, Taco Bell returned to Monterrey, projecting an American image with an Americanized menu that included french fries, but it closed in January 2010 due to low patronage.
=== Pharmacodynamics === The mechanism of action of traneurocin is either unknown or undisclosed. However, it has been described as acting as a positive allosteric modulator of the AMPA receptor and has been found to increase brain-derived neurotrophic factor (BDNF) levels. It has also been found to act as a positive allosteric modulator of the GABAA receptor. The drug is described as having neuroprotective, neurogenesis-stimulating, and pro-cognitive or nootropic effects. It has also been reported to have antihypoxic and anxiolytic properties.
== Career == Eaton spent his academic career within the Department of Environmental and Occupational Health Sciences (DEOHS) at the University of Washington School of Public Health. He served as the Director of the UW Toxicology Program from 1986 to 1991. From 1995 to 2015, he led the National Institute of Environmental Health Sciences (NIEHS) Core Center as the founding director of the Center for Ecogenetics and Environmental Health (CEEH). In university-wide administration, Eaton served as Associate Dean for Research in the School of Public Health and Community Medicine from 1999 to 2005. He served as Associate Vice Provost for Research from 2006 to 2013, Interim Vice Provost for Research from 2010 to 2011, and Dean and Vice Provost of The Graduate School from 2013 until 2018. He retired as Professor Emeritus in 2019.
Sources: en.wikipedia.org
Most of the world's cocaine is produced in South America, particularly in the Andean region. The environmental destruction caused by the production of cocaine has been well documented, with reports made the UN and other government bodies. Due to the illegal nature of coca production, farmers make little effort in soil conservation and sustainability practices as seen in the high mobility and short life of coca plots in Colombia. One of the major implications of cocaine production is deforestation as large areas of forest are cleared for coca cultivation. The UNODC approximated that 97,622 hectares of primary forest were cleared for coca cultivation during 2001–2004 in the Andean region. This further causes habitat destruction, especially in biodiversity hotspots, areas rich in a variety of species. Such areas are chosen for coca cultivation due to their remote locations, minimising chances of detection. Deforestation impacts soil erosion which further inhibits the survival of native species. The use of pesticides can also severely affect the environment. Farmers are able to use unregulated and highly toxic pesticides due to the clandestine nature of drug production. The use of such pesticides can have both direct and indirect effects on the ecosystem. Where lethal levels of exposure directly cause the death of fauna, which is further carried up the food chain where secondary feeders who consume the poisoned animals are also impacted.
=== EPMA (Electron Plate Analysis) === EPMA determines elemental composition by bombarding a sample with an electron beam, causing it to emit characteristic X-rays. These X-rays are detected and analysed to identify elements. With high precision, EPMA is widely used in materials science, geology, and other fields. It helps understand material properties and investigate atomic-level details. By comparing detected X-rays with known standards, EPMA quantifies elements present in the sample.
=== Global food distribution === Along with Archer Daniels Midland, Bunge, and Cargill, the Louis Dreyfus Company is one of the four "ABCD" companies that dominate world agricultural commodity trading.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.